Invivyd demonstrated strong commercial momentum in Q4 2025 with PEMGARDA net product revenue growing 31% sequentially. The company significantly strengthened its balance sheet, ending the year with $226.7 million in cash, while successfully reducing annual operating expenses by nearly half compared to the prior year. Focus is now shifting toward the pivotal Phase 3 DECLARATION trial for VYD2311.

The company generated $11.3 million in PEMGARDA revenue while reducing R&D expenses and net loss compared to the same period last year. Invivyd remains focused on reaching near-term profitability and bolstering its antibody pipeline.

Invivyd reported $9.3 million in PEMGARDA net product revenue for Q3 2024, an increase from $2.3 million in Q2 2024. The company ended the quarter with $106.9 million in cash and cash equivalents and is targeting near-term profitability. They highlight the updated PEMGARDA Fact Sheet and the initiation of dosing in the Phase 1 clinical trial of VYD2311.

Invivyd launched PEMGARDA commercially in Q2 2024, generating $2.3 million in net product revenue. The company ended the quarter with $147.9 million in cash and cash equivalents and is preparing for the peak fall/winter respiratory virus season.

Invivyd launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis and reported interim data from the CANOPY Phase 3 trial. The company ended Q1 with $189.4 million in cash and expects to end 2024 with at least $75 million based on anticipated revenue of $150-$200 million.

Invivyd announced financial results for the full year ended December 31, 2023, highlighted by the emergency use authorization of PEMGARDA for pre-exposure prophylaxis of COVID-19 in certain adults and adolescents. The company's cash and cash equivalents totaled $200.6 million as of December 31, 2023. They expect to provide insights on key launch metrics as time progresses.